AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02812043 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1,064nm Long-pulsed Nd:YAG
Description: Long-pulsed 1,064nm will be used for the treatment of onychomycosis which wll use 35-45 J/cm2 spot size 4, frequency 1 Hz for 2 passes on the infected nails
Study NCT02140060 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Travoprost solution vehicle
Description: Inactive ingredients used for masking purposes
Study NCT02140060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost solution vehicle
Description: Inactive ingredients used for masking purposes
Study NCT02140060 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brinzolamide suspension vehicle
Description: Inactive ingredients used for masking purposes
Study NCT02812043 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amorolfine
Description: Amorolfine nail lacquer will be applied by the patient once a week on the infected nails
Study NCT01448798 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Application of a hemostatic gelatin-thrombin matrix
Description: Hemostatic gelatin-thrombin matrix is used for hemostasis during nerve-sparing dissection of the prostate.
Study NCT01448798 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Use of mono- and bipolar electrocautery and surgical clips
Description: Mono- and bipolar electrocautery and surgical clips are used for hemostasis during nerve-sparing dissection of the prostate.
Study NCT02763865 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MagVenture MagProx100 Stimulator with a Cool-B65 A/P coil
Description: Active rTMS administration (1Hz, 1,200sec, 110% resting motor threshold (rMT); 1200 pulses total.~Resting motor threshold assessment the TMS machine will initially be set to 50% of its maximal output.
Study NCT03370705 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACE inhibitor
Description: ACE inhibitor 20mg once daily per oral route
Study NCT03370705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACE inhibitor
Description: ACE inhibitor 20mg once daily per oral route
Study NCT03537300 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DCF muscles training using pressure biofeedback in addition to conventional exercises
Description: DCF muscles training using pressure biofeedback in addition to conventional exercises
Study NCT03537300 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: conventional exercises
Description: conventional exercises
Study NCT02745730 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Glucose
Study NCT02745730 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fructose
Study NCT02763865 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: eSHAM system
Description: implemented in conjunction with the Cool-B65 A/P coil to effectively blind participants to rTMS treatment (active or sham)
Study NCT02745730 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sucralose
Study NCT02745730 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Allulose
Study NCT04455711 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Iv
Description: Bolus dose of 1.5 mg/kg lidocaine was injected immediate after operation.
Study NCT04765631 — intervention group
Intervention type: OTHER
Intervention: Patients with Type 2 diabetes
Description: No intervention
Study NCT03536130 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electronic chest drainage system
Description: Patients in the intervention arm are connected to Drentech Palm Evo with single standard chest tube (28 Ch) immediately after closure of the chest. Patients with digital devices are managed by setting the pump to -20 cmH2O until the morning of postoperative day (POD) 1 and then setting the pump on physiologic mode (0 cmH2O) thereafter. Management of chest tube drainage and decision for chest tube removal will be dictated by clinical signs, symptoms and surgeon preference following standard clinical practice of general thoracic patients
Study NCT03063047 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PD21871AA
Description: A 100s size menthol cigarette.
Study NCT03063047 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PD21872AA
Description: A 100s size menthol cigarette.
Study NCT04765631 — intervention group
Intervention type: OTHER
Intervention: Placebo
Description: Placebo comparator
Study NCT00486811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tapentadol ER (100 to 250 mg twice daily)
Description: 50, 100, 150, 200, 250 mg twice a day (BID) during 15 weeks (3 weeks titration and 12 weeks maintenance)
Study NCT00486811 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo (twice daily)
Description: Matching Placebo during 15 weeks (3 weeks titration and 12 weeks maintenance)
Study NCT00486811 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone CR (20 to 50 mg twice daily)
Description: 10, 20, 30, 40, 50 mg twice a day (BID) during 15 weeks (3 weeks titration and 12 weeks maintenance)
Study NCT00926315 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: calcitriol
Description: Post menopausal patients will receive Calcitriol 0.50 mcg PO per day for 1 month.
Study NCT00926315 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcitriol
Description: calcitriol 0.25 mcg PO bid
Study NCT02919358 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music
Study NCT02919358 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No music.
Description: This is the control group.
Study NCT04455711 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Continuous infusion of remifentanil 1.5 ng/ml until extubation
Study NCT04455711 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Remifentanil
Description: Continuous infusion of remifentanil 1.5 ng/ml until extubation
Study NCT03668574 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: Aerobic exercise that is defined as a form of exercise lasting 15 to 60 minutes continuous and intensity of 60% to 90% of maximal heart rate.
Study NCT03668574 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Group
Description: Will be treated with pulsed 5-minute ultrasound and pulsed short-wave diathermy for 25 minutes. The devices will be used with disconnected internal cables to obtain the placebo effect
Study NCT01671280 — intervention group
Intervention type: DRUG
Intervention: Azithromycin IV
Description: The recommended dose of ZITHROMAC (azithromycin for injection) for the treatment of adult patients with pneumonia due to the indicated organisms is: 500 mg as a single daily dose by the intravenous route for at least two days. Intravenous therapy should be followed by azithromycin by the oral route at a single, daily dose of 500 mg, administered as two 250-mg tablets to complete a 7- to 10-day course of therapy.~The recommended dose of ZITHROMAC (azithromycin for injection) for the treatment of adult patients with pelvic inflammatory disease due to the indicated organisms is: 500 mg as a single daily dose by the intravenous route for one or two days. Intravenous therapy should be followed by azithromycin by the oral route at a single, daily dose of 250 mg to complete a 7-day course of therapy.
Study NCT02299960 — intervention group
Intervention type: DEVICE
Intervention: Endo-PAT
Description: Analysis of endothelial function through pulse-amplitude-tonometry
Study NCT02299960 — intervention group
Intervention type: DEVICE
Intervention: NICOM
Description: Non-invasive measurement of cardiac output
Study NCT00622895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Given IV
Study NCT00622895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolic Acid
Description: Given PO
Study NCT00622895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: Given PO
Study NCT00027872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tipifarnib
Description: Given orally
Study NCT00027872 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00536393 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Study NCT00536393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin pegylated
Study NCT02671513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR6390
Description: SHR6390 either 50mg,75mg,100mg,125mg,150mg,175mg given orally, QD
Study NCT00185198 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testogel (Testosterone, BAYV001915)
Description: 50mg (5g gel sachet), 75mg (5g+2.5g sachet) or 100mg (2x5g sachet) per day applied to the skin of the shoulders, arms or abdomen for 18 months
Study NCT04386759 — intervention group
Intervention type: OTHER
Intervention: Cohort
Description: None. Only implementation of a cohort with data collection via individual self-questionnaires and administrative services for contextual data.
Study NCT01925092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mifepristone
Description: tablets
Study NCT01885455 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual care includes: complete staging work-up (CT/PET scan and possible mediastinoscopy), surgical consultation with a general or cardiothoracic surgeon, cardiac clearance and/or pulmonary function testing (if deemed necessary by the evaluating surgeon), surgical resection (wedge resection, lobectomy, pneumonectomy, or radiosurgery, as indicated by the size and location of the tumor), and adjuvant therapy (radiotherapy and/or chemotherapy, as determined by the intraoperative findings and pathology results).
Study NCT01885455 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention Arm
Description: The proposed Intervention (EPDPN) will be administered by the PNs at the intervention sites on an outpatient basis. Several defining, fundamental characteristics of the PNs will ensure consistency of the intervention delivery across the various study sites.
Study NCT01612520 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: telecoaching
Description: The COACH program trains patients to 'drive' the process of achieving and maintaining the target levels for their risk factors while working in association with their GP. The telephone coaching is aimed at improving self-efficacy by adhering to the prescribed therapy and making relevant behavior changes.~The coaching model is a continuous five-stage coaching cycle: Stage 1. Finding out what the patient knows; Stage 2. Telling the patient what they should know; Stage 3. Assertiveness training; Stage 4. Setting an action plan; Stage 5. Reassessment at the next coaching session (monitoring).~The coach monitors and registers: the biomedical risk factors, the lifestyle/behavioral risk factors and use of the recommended medications. Coaching is focused on eliminating the knowledge gap and motivating the patient to apply the appropriate lifestyle and medical therapy.
Study NCT02359617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin delivery
Description: Subcutaneous insulin (100 U/ml, NovoRapid®; Novo Nordisk, Bagsvaerd, Denmark) delivery with an insulin pump (Vibe-TM; Animas Corp., West Chester, PA, USA) and an insulin infusion cannula (SOF-SET MICRO QR 6mm; Medtronic MiniMed, USA) placed at the same site as the continuous glucose sensor.
Study NCT02359617 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: glucose sensing
Description: Glucose sensing with a continuous glucose sensor (Dexcom G4 Platinum Sensor; Dexcom Inc., San Diego, USA) placed at the site of subcutaneous insulin delivery.
Study NCT02754622 — intervention group
Intervention type: OTHER
Intervention: Observational Group
Description: Indirect calorimetry measurement during Physical Rehabilitation. Observing planned physical rehabilitation session to determine the rehabilitation activity achieved with IC utilised to determine the number of calories used per session
Study NCT01270919 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: BioDuct Meniscal Repair Device
Description: The BioDuct® Meniscal Repair Device is a small, cannulated, arthroscopically implanted, bioabsorbable conduit that has length sizes of 5, 7 and 9 mm. Based on the concept of trephination for treating meniscal tears in the red-white zone, the BioDuct® Meniscal Repair Device is designed to create a vascular access channel between the vascular-rich and cell-rich synovium and the meniscal tear. This channel allows for the flow of blood from the vascular to the avascular tissue to promote repair of the meniscus.~The BioDuct® Meniscal Repair Device is not used across meniscal tears, like other fixation devices. The BioDuct® Meniscal Repair Device is used in conjunction with suturing and helps provide vascular access, while the sutures help provide fixation. Based on the Inclusion Criteria of this protocol, there can be a maximum of three BioDuct® Meniscal Repair Devices utilized for the meniscal tear.
Study NCT00660647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: Adalimumab injection 0.8 ml (40 mg) s.c. every second week in up to 2 years
Study NCT00660647 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline injection 0.9%, 0.8 ml s.c. every second week up to 2 years
Study NCT02615847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantinhydrochlorid
Description: Memantin Mepha® Lactabs (memantinehydrochlorid) will be provided as 5 mg, 10 mg, 15 mg and 20 mg tablets, packed in blister.~The study drug will be taken once a day per os, during 12 month.
Study NCT04320147 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artemia
Description: Before prostate biopsy, all patients be preceded by mpMRI.MR-targeted biopsy using Artemis device fusion of MRI and ultrasound images would be performed. MR targeted biopsy would be performed by radiologist.
Study NCT01848340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1265744B (sodium salt) containing 14C-GSK1265744B
Description: A white to slightly colored nonsterile crystalline powder for oral solution
Study NCT01848340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 150 mg GSK1265744B
Description: This is GSK1265744B (sodium salt of GSK1265744), lactose monohydrate, Microcrystalline cellulose, hypromellose, sodium lauryl sulfate, croscarmellose sodium, magnesium stearate, Opadry film-coating, white OY-S-28876 tablet
Study NCT01848340 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Microcrystalline cellulose, Opadry film-coating, white OY-S-28876 tablet
Study NCT02865122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NTRA-9620
Description: Oral daily dose
Study NCT02865122 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral daily dose
Study NCT02472366 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: ILUVIEN
Study NCT01745783 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bone marrow mesenchymal stem cells autologous
Description: Infusion of mesenchymal cells from autologous bone marrow in a dose of 1-2x106 cells / kg
Study NCT01745783 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: Lactated Ringer's solution, 2.5% glucose and 1% human albumin.
Study NCT00911781 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: We are only asking for photographs from parents.
Study NCT01510262 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored Socio-Contextual Intervention
Description: 1. Develop strengths based case management intervention using input from interviews with repeat STI patients, consultants, \& piloting.~2. Recruit/enroll in the intervention 500 subjects (50% women; African American focus).~3. After subjects receive STI diagnosis, treatment,\& partner notification services, randomly assign subjects to:~   A. The STI strengths-based prevention case management, or B. Standard care.~4. Assess participants' risk behavior, determinants of behavior \& quality of life. Investigators will assess the incidence of new STI \& test the efficacy of the intervention relative to control.~5. Conduct a qualitative evaluation. Investigators will sample repeaters and non-repeaters from the experimental group.~6. Conduct cost effectiveness analyses of intervention compared to the standard.
Study NCT01510262 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Currently, the total time spent in an STI exam w/men is 30 minutes \& 60 w/women. More time is devoted to patients with sexual assault hx. Reason for the visit, symptoms, STI hx, contraception, condom use, number/gender of partners \& number/type of sexual activities are assessed. The nurse takes a health hx and asks about typical HIV risks behavior. Due to time the risk assessment is 5 minutes. A risk reduction kit including condoms is issued. Information includes symptoms/treatment of STI, location of sexual health clinics, location of free condoms \& testing/treatment resources. Referral information is provided when needed \& more involved w/sexual assault survivors. Partner notification is conducted w/syphilis and HIV. This didactic process follows the medical model.
Study NCT00262925 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: alemtuzumab
Description: Given subcutaneously
Study NCT00262925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: asparaginase
Description: Given IM
Study NCT00262925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given IV or orally
Study NCT00262925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given orally
Study NCT00262925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV
Study NCT00262925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mercaptopurine
Description: Given orally
Study NCT00262925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine
Description: Given IV
Study NCT02325778 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CTI ablation Timing
Description: The timing of when the CTI ablation is performed. There are no other relevant interventions used in the procedure.
Study NCT01741662 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: neuropsychological evaluation
Study NCT05112133 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mulberry leaf extract
Description: Oral administration
Study NCT05112133 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Water
Description: Oral administration
Study NCT03547570 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive heavy shoulder resistance training
Description: The training programme includes five exercises identified in literature to target scapular and rotator cuff muscles.
Study NCT03838874 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low-Dose Bupivacaine
Description: 10 mg (2 mL of 0.5%) administered as an isobaric spinal anesthetic
Study NCT03838874 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mepivacaine
Description: 70 mg (3.5 mL of 2%) administered as an isobaric spinal anesthetic
Study NCT04170413 — intervention group
Intervention type: DRUG
Intervention: CeVUS
Description: Contrast enhanced voiding urosonography
Study NCT00831844 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cixutumumab
Description: Given IV: Week 1 day 1, 9 mg/kg/dose over 1 hour. Week 2 Day 8, 9 mg/kg/dose over 1 hour. Week 3 Day 15, 9 mg/kg/dose over 1 hour. Week 4 Day 22, 9 mg/kg/dose over 1 hour.
Study NCT01938339 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET/MR
Description: Multi-radiotracer PET/MR will be performed in patients with primary and recurrent prostate cancer
Study NCT00185198 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5g gel sachet, 5g+2.5g sachet or 2x5g sachets per day applied to the skin of the shoulders, arms or abdomen for 6 months followed by 12 months treatment with testosterone 1% gel as described for arm 1
Study NCT00796523 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Happiest Baby videotape
Description: a videotape demonstrating the Happiest Baby on the Block technique for calming crying infants
Study NCT00796523 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: control videotape
Description: a videotape with general newborn care instructions
Study NCT00761644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxil
Description: Day 1 of each 21 day cycle, beginning dose level 10 mg/m\^2 by vein over 3 hours.
Study NCT00831844 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00761644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Day 1 of each 21 day cycle, beginning dose level 5 mg/kg by vein over 90 minutes.
Study NCT00761644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: Days 1, 8 \& 15 of 21 Day Cycle, beginning dose level 12.5 mg by vein over 30 to 60 minutes.
Study NCT02527577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RopivacaIne chlorhydrate
Description: 3mg/kg injection Hour (H) 0, H12 ; H24, H36 ; H48